Schedule 13G ownership disclosure

Monte Rosa Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 61225M102

Event date: 2025-01-24

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 2,257,204.00 · Class: 3.7%

  • BVF I GP LLC

    Shares: 2,257,204.00 · Class: 3.7%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 1,823,443.00 · Class: 3.0%

  • BVF II GP LLC

    Shares: 1,823,443.00 · Class: 3.0%

  • Biotechnology Value Trading Fund OS LP

    Shares: 228,202.00 · Class: 0.4%

  • BVF Partners OS Ltd.

    Shares: 228,202.00 · Class: 0.4%

  • BVF GP HOLDINGS LLC

    Shares: 4,080,647.00 · Class: 6.6%

  • BVF PARTNERS L P/IL

    Shares: 4,393,210.00 · Class: 7.2%

  • BVF INC/IL

    Shares: 4,393,210.00 · Class: 7.2%

  • LAMPERT MARK N

    Shares: 4,393,210.00 · Class: 7.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-000213
Form type
SCHEDULE 13G
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Jan 31, 2025
Reporting period
Jan 24, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub